Koyfin Home > Directory > Health Care > Revance Therapeutics > Total Debt / EBITDA

Revance Therapeutics Total Debt / EBITDA Chart (RVNC)

Revance Therapeutics annual/quarterly Total Debt / EBITDA from 2012 to 2020.
  • Revance Therapeutics Total Debt / EBITDA for the quarter ending June 06, 2020 was $-1m a 79.93% decrease of -1m year over year
  • Revance Therapeutics Total Debt / EBITDA for the last 12 months ending June 06, 2020 was $-1m a 80.12% decrease of -1m year over year
  • Revance Therapeutics Annual Total Debt / EBITDA for 2019 was $0m a 91.49% decrease of 0m from 2018
  • Revance Therapeutics Annual Total Debt / EBITDA for 2017 was $0m a -326.49% increase of 0m from 2016
  • Revance Therapeutics Annual Total Debt / EBITDA for 2016 was $0m a -75.28% increase of 0m from 2015
Other Ratios Metrics:
  • Revance Therapeutics Total Debt / Capital for the quarter ending March 03, 2018 was $0m a -426.67% decrease of -2m year over year
  • Revance Therapeutics Other Liabilities for the quarter ending September 09, 2018 was $19m a 68.91% increase of 13m year over year
  • Revance Therapeutics Total Debt / Equity for the quarter ending March 03, 2018 was $0m a -436.21% decrease of -2m year over year
View Chart On Koyfin

Quarterly RVNC Total Debt / EBITDA Data

06/2020$-1m
03/2020$-1m
12/2019$0m
09/2019$0m
06/2019$0m
03/2019$0m
03/2018$0m
12/2017$0m
09/2017$0m
06/2017$0m

Annual RVNC Total Debt / EBITDA Data

2019$0m
2017$0m
2016$0m
2015$0m
2014$0m
2013$-1m
2012$-3m
2011$-3m